SCHEMBL2941497

SCHEMBL2941497

N#CCOc1ccc2cc(-c3cnc(Cc4ccc5ccccc5c4)o3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MAPT P10636 7/20 0.38
MAPK1 P28482 4/20 0.38
KDM4E B2RXH2 3/20 0.38
TSHR P16473 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
FFAR1 O14842 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950719 0.92 MAPK1 (0.38) LMNANPSR1NPC1RAB9AMAPT
SCHEMBL2950785 0.85 CYP1A2 (0.46) LMNANPSR1NPC1RAB9AMAPT
SCHEMBL2943816 0.82 PTPN7 (0.56) LMNANPSR1NPC1RAB9AMAPT
SCHEMBL2945132 0.80 TSHR (0.52) LMNANPSR1NPC1RAB9AMAPT
SCHEMBL2943719 0.80 ALOX5 (0.48) FFAR1CYP11B1CYP11B2ALOX5NOTUM
SCHEMBL2948596 0.79 MEN1 (0.42) LMNANPSR1NPC1RAB9AMAPT
SCHEMBL11026671 0.75 AGXT (0.57) LMNANPSR1NPC1RAB9AMAPT
SCHEMBL2942935 0.75 CYP11B1 (0.49) LMNANPSR1NPC1RAB9AMAPT
SCHEMBL2942318 0.74 PTPN7 (0.53) LMNANPC1RAB9AALDH1A1POLB
SCHEMBL22556752 0.72 CYP11B1 (0.47) MAPTKDM4ETSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754747-B2 Oxazolo-naphthyl acids WYETH LLC (US) 2010-07-13 US disclosed
EP-1781645-A1 OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES Wyeth (US) 2007-05-09 EP disclosed
US-20060052348-A1 Oxazolo-naphthyl acids WYETH (US) 2006-03-09 US disclosed
WO-2006023865-A1 OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES WYETH (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052348-A1 Oxazolo-naphthyl acids SERPINE1, SERPINB1, SERPINC1 LMNA 816/4885NPSR1 1012/4885NPC1 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.